B
Bull
Bull · 25%LENZ
$37.95
Scenario price
$3.010
-0.392 (-13.01%)At close
Loading chart…
- High
- 3.440
- Open
- 3.440
- VWAP
- 3.15
- Volume
- 737.00K
- Mkt Cap
- —
- Low
- 3.000
- Amount
- 2.32M
- EV/EBITDA, TTM
- -0.23
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
AI analysis of LENZ Therapeutics Inc (LENZ)
BuyLENZ Therapeutics Inc is a good buy right now at a current price of $3.05, especially considering its recent sales growth of 50% in Q3 2026, which indicates increasing market acceptance. The stock is currently oversold with an RSI of 36.13, suggesting potential for a rebound. However, the main risk is its significant year-to-date decline of 80.94%, which highlights volatility and uncertainty in the stock's recovery.
Valuation Metrics
The current forward P/E ratio for LENZ Therapeutics Inc (LENZ) is 0.00, compared to its 5-year average forward P/E of -10.36.
Alphio AI Price Scenarios for LENZ
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding LENZ
Events Timeline
News
8.510-28NewsfilterLENZ Therapeutics Reports 50% Q3 Sales Growth and Strategic Reorganization
2.007-14NASDAQ.COMLenz Therapeutics Shares Enter Oversold Territory
- 8.507-06Newsfilter
LENZ Launches Telehealth Platform for VIZZ
- 7.506-24Newsfilter
LENZ and Arrotex Sign Exclusive License Agreement for VIZZ in Australia and New Zealand
8.506-12NASDAQ.COMBiotech Sector Sees Surge in FDA and Global Approvals
LENZ FAQ — answered by Alphio AI
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
LENZ Therapeutics Inc is a good buy right now at a current price of $3.05, especially considering its recent sales growth of 50% in Q3 2026, which indicates increasing market acceptance. The stock is currently oversold with an RSI of 36.13, suggesting potential for a rebound. However, the main risk is its significant year-to-date decline of 80.94%, which highlights volatility and uncertainty in the stock's recovery.
Community
More ↗
$LENZ: LENZ Theutics approves reorganization, cutting 75% of staff and targeting over 50% lower 2027 operating expenses.
Show moreRelated articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.